- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02532283
A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection
March 26, 2020 updated by: Janssen Research & Development, LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly Hospitalized Patients With Influenza A Infection
The purpose of this study is to evaluate the Pharmacokinetic parameters of JNJ-63623872 in combination with oseltamivir in elderly participants (aged 65 to <= 85 years) compared to adults (aged 18 to <= 64 years) with influenza A infection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomized (study medication assigned to participants by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), placebo-controlled, multicenter (when more than one hospital or medical school team work on a medical research study) study to evaluate the effect of JNJ-63623872 in combination with oseltamivir in participants with influenza A infection.
The study consists of 3 Phases: Screening visit (1 Day), participants who meet all eligibility criteria will be randomized in a 2:1 ratio to receive study drug in double-blind treatment Phase (7 Days) and follow up Phase (21 Days).
The duration of participation in the study for each participant is approximately 28 Days.
Primarily Pharmacokinetic parameters of JNJ-63623872 will be measured.
Participants' safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairns, Australia
-
South Brisbane, Australia
-
Westmead, Australia
-
-
-
-
-
Aalst, Belgium
-
Bruxelles, Belgium
-
Leuven, Belgium
-
-
-
-
-
Passo Fundo, Brazil
-
Porto Alegre, Brazil
-
Sao Paulo, Brazil
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada
-
-
Quebec
-
Québec, Quebec, Canada
-
-
-
-
-
Dijon, France
-
Grenoble, France
-
Limoges, France
-
Lyon, France
-
Nantes, France
-
Paris, France
-
Poitiers, France
-
Rennes, France
-
Saint-Priest en Jarez, France
-
Tours Cedex 9, France
-
-
-
-
-
Donaustauf, Germany
-
Jena, Germany
-
-
-
-
-
Hong Kong, Hong Kong
-
-
-
-
-
Kota Bharu, Malaysia
-
Kuala, Malaysia
-
Kuala Lumpur, Malaysia
-
Kuching, Malaysia
-
Melaka, Malaysia
-
Miri, Malaysia
-
Sungai Buloh, Malaysia
-
Taiping, Malaysia
-
-
-
-
-
Rotterdam, Netherlands
-
Utrecht, Netherlands
-
Zutphen, Netherlands
-
-
-
-
-
Hamilton, New Zealand
-
-
-
-
-
Singapore, Singapore
-
-
-
-
-
Alicante, Spain
-
Barcelona, Spain
-
Bizkaia, Spain
-
Elche, Spain
-
Granada, Spain
-
Madrid, Spain
-
Mataró, Spain
-
San Sebastián, Spain
-
Vigo, Spain
-
-
-
-
-
Malmö, Sweden
-
Umeå, Sweden
-
Uppsala, Sweden
-
-
-
-
-
Ankara, Turkey
-
Eskişehir, Turkey
-
Istanbul, Turkey
-
Izmir, Turkey
-
Trabzon, Turkey
-
-
-
-
California
-
Fresno, California, United States
-
Long Beach, California, United States
-
Stanford, California, United States
-
-
Florida
-
Atlantis, Florida, United States
-
Miami, Florida, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Michigan
-
Detroit, Michigan, United States
-
Royal Oak, Michigan, United States
-
Troy, Michigan, United States
-
-
Minnesota
-
Minneapolis, Minnesota, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
New Jersey
-
Teaneck, New Jersey, United States
-
-
North Carolina
-
Winston-Salem, North Carolina, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant requires hospitalization to treat influenza infection and/or to treat complications of influenza infection
- Participant tested positive for influenza A infection within 1 day of signing of the informed consent form (ICF)/assent form using a polymerase chain reaction (PCR)-based rapid molecular diagnostic assay
- Participants must be capable of swallowing study medication tablets and capsules
- Each participant (or their legally acceptable representative) must sign an ICF indicating that he or she understands the purpose of and procedures required for the study and is willing to participate in the study
- Participant must be willing and able to adhere to the prohibitions and restrictions specified in the protocol
Exclusion Criteria:
- Participant received more than 3 doses of the influenza antiviral medication oseltamivir, zanamivir, or peramivir since the start of the influenza symptoms, or ribavirin within 6 months prior to Screening
- Participant is unwilling to undergo regular nasal Mid-turbinate (MT) swabs or has any physical abnormality which limits the ability to collect regular nasal specimens
- Participant is immunocompromised, whether due to underlying medical condition (example, malignancy) or medical therapy (example, medications, chemotherapy, radiation, post-transplant)
- Participant is undergoing peritoneal dialysis, hemodialysis, or hemofiltration
- Participant has an estimated glomerular filtration rate (eGFR) less than or equal to (<=)30 milliliter (mL)/minute (min)/1.73 meter^2 (m^2) according to the Modification of Diet in Renal Disease (MDRD) equation, assessed at Screening or based on the most recent clinically relevant creatinine value if available
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JNJ-63623872 plus Oseltamivir
Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
|
Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
|
Experimental: Placebo plus Oseltamivir
Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
|
Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
Participants will be administered placebo tablets orally twice daily for 7 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax) of Pimodivir
Time Frame: Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3
|
Cmax is the maximum observed plasma concentration.
As per planned analysis, results are presented by age groups (65 to less than or equal to [<=] 85 years and 18 to <=64 years).
|
Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3
|
Minimum Observed Plasma Concentration (Cmin) of Pimodivir
Time Frame: Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3
|
Cmin is the minimum observed plasma concentration.
As per planned analysis, results are presented by age groups (65 to <= 85 years and 18 to <=64 years).
|
Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3
|
Area Under the Plasma Concentration-time Curve From Time of Administration to 12 Hours After Dosing (AUC [0-12]) of Pimodivir
Time Frame: Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3
|
AUC (0-12) is the area under the plasma concentration-time curve from time zero to 12 hours after dosing of pimodivir.
As per planned analysis, results are presented by age groups (65 to <= 85 years and 18 to <=64 years).
|
Pre-dose, 1, 2, 4, 6, 8, 10 and 12 hours post-dose on Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious AEs (TESAEs)
Time Frame: Up to 28 Days
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product.
An AE does not necessarily have a causal relationship with treatment and therefore can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with use of a medicinal product, whether or not related to that medicinal product.
TEAEs were defined as AEs that were reported or worsened on after start of study drug(s) dosing through safety follow-up visit.
A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulting in any of following outcomes: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.
|
Up to 28 Days
|
Time to Influenza A Viral Negativity
Time Frame: Up to 14 Days
|
Time to influenza A viral negativity was determined based on quantitative reverse transcription polymerase chain reaction (qRT-PCR).
A participant was considered influenza A viral negative at the time point that the first negative nasal midturbinate (MT) swab was recorded (in days).
Viral Load Limit of detection (LOD) = 2.18 log10 viral particles per milliliter (vp/mL).
Results less than (<) limit of quantification (LOQ) and greater than (>) LOD (target detected) are imputed with 2.12 log10 vp/mL, results <LOD (target not detected) are imputed with 0 log10 vp/mL.
|
Up to 14 Days
|
Influenza Viral Load Over Time
Time Frame: Baseline, Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14
|
Influenza viral load over time (Log 10 viral particles per milliliter [vp/mL]) was measured by qRT-PCR.
Viral Load LOD = 2.18 log10 vp/mL.
Results < LOQ and > LOD (target detected) are imputed with 2.12 log10 vp/mL and results <LOD (target not detected) are imputed with 0 log10 vp/mL.
|
Baseline, Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14
|
Rate of Decline in Viral Load
Time Frame: Up to Day 7
|
Rate of decline in viral load (Log10 viral particles per milliliter per day [log10 vp/mL/day]) during treatment was measured by qRT-PCR.
Viral Load Limit of quantification (LOQ) = 2.18 log10 vp/mL, LOD = 2.05 log10 vp/mL.
Results < LOQ and greater than > LOD (target detected) are imputed with 2.12 log10 vp/mL.
Results <LOD (target not detected) are imputed with 0 log10 vp/mL.
|
Up to Day 7
|
Area Under the Plasma Concentration-time Curve (AUC) of Viral Load
Time Frame: Baseline up to Day 8
|
Viral load AUC was determined by qRT-PCR assay of nasal swabs.
Viral Load LOQ = 2.18 log10 vp/mL, LOD = 2.05 log10 vp/mL.
Results <LOQ and >LOD (target detected) are imputed with 2.12 log10 vp/mL.
Results <LOD (target not detected) are imputed with 0 log10 vp/mL.
|
Baseline up to Day 8
|
Percentage of Participants With Influenza Complications
Time Frame: Up to 28 Days
|
Percentage of participants with following Influenza Complications: bacterial pneumonia (culture confirmed where possible), bacterial superinfections, respiratory failure, pulmonary disease (example, asthma, chronic obstructive pulmonary disease [COPD]), cardiovascular and cerebrovascular disease (example, myocardial infarction, congestive heart failure [CHF], arrhythmia, stroke) and all complications were reported.
|
Up to 28 Days
|
Change From Baseline in Influenza Patient-Reported Outcome Questionnaire (FLU-PRO) Total Score
Time Frame: Baseline, Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, and 33
|
FLU-PRO assesses 32 influenza symptoms in each of the following body areas (domains): Nose, Throat, Eyes, Chest/Respiratory, Gastrointestinal and Body/Systemic .
Participants rate each symptom on a 5-point ordinal scale, with higher scores indicating a more frequent sign or symptom.
For 27 of the items, the scale is as follows: 0 ("Not at all"), 1 ("A little bit"), 2 ("Somewhat"), 3 ("Quite a bit"), and 4 ("Very much").
For 5 items, severity is assessed in terms of numerical frequency, that is (i.e), vomiting or diarrhea (0 times, 1 time, 2 times, 3 times, or 4 or more times); with frequency of sneezing, coughing, and coughed up mucus or phlegm evaluated on a scale from 0 ("Never") to 4 ("Always").The FLU-PRO total score is computed as a mean score across all 32 items comprising the instrument.
Total scores can range from 0 (symptom free) to 4 (very severe symptoms).
|
Baseline, Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, and 33
|
Time to Improvement of Vital Signs
Time Frame: Up to 28 Days
|
Time to improvement of vital signs was defined as the time from first study treatment to when at least 4 of 5 symptoms (temperature, blood oxygen saturation, heart rate, systolic blood pressure, and respiration rate) had recovered, including normalization of temperature and blood oxygen saturation.
Resolution criteria for vital signs: for Temperature: oral temperature less than or equal to (<=) 36.5 degree Celsius (C) for elderly and <=37.2
C for adults; for oxygen saturation: greater than or equal to (>=) 92 percent (%) on room air without supplemental oxygen; for respiratory rate: <= 24 per minutes; for heart rate: <= 100 per minutes and for systolic blood pressure: >= 90 millimeters of mercury (mmHg).
|
Up to 28 Days
|
Time to Improvement of Respiratory Status
Time Frame: Up to 28 Days
|
The time to improvement of respiratory status was defined as the time from first study treatment until the first assessment of a successive series of 3 recording where normalization of blood oxygen saturation and respiration rate occurred at respiration rate <=24 per minutes).
|
Up to 28 Days
|
Percentage of Participants With Clinical Outcome Based on Ordinal Scale
Time Frame: Day 8
|
The ordinal scale was used to assess participant's clinical outcome.
It consists of 6 categories or clinical states that are exhaustive, mutually exclusive, and ordered, where 1- Death, 2- Admitted to intensive care unit (ICU) or mechanically ventilated/ extracorporeal membrane oxygenation (ECMO), 3- Non-ICU plus supplemental oxygen, 4- Non-ICU plus no supplemental oxygen, 5- Not hospitalized, but unable to continue activity, 6- Not hospitalized (NH) and continues activities.
|
Day 8
|
Number of Participants With the Emergence of Drug Resistance Mutations With Oseltamivir (OST) and Pimodivir
Time Frame: Up to 28 Days
|
Number of participants with emergence (from baseline) of drug resistance mutations detected by genotype or phenotype were reported.
|
Up to 28 Days
|
Time to Return to Premorbid Functional Status
Time Frame: Up to Day 33
|
Time to return to premorbid functional status (time to return usual activities) was defined as time in hours from the first dose of investigational product till the first one of 2 successive cases where the response is 'Yes' on FLU-PRO additional question 7 (Have you returned to your usual activities today?).
|
Up to Day 33
|
Time to Hospital Discharge
Time Frame: Up to 28 Days
|
Time to hospital discharge was calculated from the date of first study drug intake during hospitalization up to date of discharge.
|
Up to 28 Days
|
Time to Return to Usual Health
Time Frame: Up to Day 33
|
Time to return to usual health was defined as the time in hours from the first dose of investigational product till the first one of 2 successive cases where the response is 'Yes' on FLU-PRO additional question 9 (Have you returned to your health today?).
|
Up to Day 33
|
Time to Significant Reduction in FLU-PRO Influenza Symptom Severity
Time Frame: Up to Day 33
|
Time to significant reduction in influenza symptom severity (mild/none) is time from first dose of investigational drug until first of 2 successive recordings in which total score for each of 2 recordings is lower or equal to 1 and all domain scores is lower or equal to 1. FLU-PRO assesses 32 influenza symptoms in body areas (domains): Nose, throat, eyes, chest, gastrointestinal, body.
Participants rate each symptom on 5-point scale, with higher scores indicates more frequent symptom.
For 27 of items, scale is as follows: 0 (Not at all), 1 (A little bit), 2 (Somewhat), 3 (Quite a bit), 4 (Very much).
For 5 items, severity is assessed in terms of numerical frequency, i.e, vomiting/diarrhea (0 times, 1 time, 2 times, 3 times, or 4 or more times); with frequency of sneezing, coughing and coughed up mucus or phlegm evaluated on scale from 0=Never to 4=Always.
FLU-PRO total score is computed as mean score across all 32 items and ranges from 0 (symptom free) to 4 (very severe symptoms).
|
Up to Day 33
|
Percentage of Participants With Significant Reduction in FLU-PRO All Influenza Symptoms (Mild or None for All Symptoms)
Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33
|
Percentage of participants with significant reduction in influenza symptom severity was defined as time from first dose of investigational product until first of 2 successive recordings in which FLU-PRO total score for each of 2 recordings <= to 1 and all FLU-PRO domain scores is <=1.
FLU-PRO assesses 32 influenza symptoms in body areas (domains): Nose, throat, eyes, chest, gastrointestinal, body.
Participants rate each symptom on a 5-point ordinal scale, with higher scores indicates more frequent symptom.
For 27 of items, scale is as follows: 0 (Not at all), 1 (A little bit), 2 (Somewhat), 3 (Quite a bit), 4 (Very much).
For 5 items, severity is assessed as numerical frequency i.e, vomiting or diarrhea (0-4 or more times); with frequency of sneezing, coughing, coughed up mucus or phlegm evaluated on a scale from 0 (Never)-4 (Always).
FLU-PRO total score is computed as a mean score across all 32 items comprising instrument and ranges from 0 (symptom free) to 4 (very severe symptoms).
|
Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 11, 2015
Primary Completion (Actual)
February 24, 2017
Study Completion (Actual)
March 15, 2017
Study Registration Dates
First Submitted
August 21, 2015
First Submitted That Met QC Criteria
August 21, 2015
First Posted (Estimate)
August 25, 2015
Study Record Updates
Last Update Posted (Actual)
March 27, 2020
Last Update Submitted That Met QC Criteria
March 26, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR107746
- 2015-003002-17 (EudraCT Number)
- 63623872FLZ2002 (Other Identifier: Janssen Research & Development, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza A Virus
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 VirusUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | OrthomyxovirdaeUnited States
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
Emergent BioSolutionsCompletedInfluenza A H3N2 | Influenza A H1N1United States, Spain, Canada, Puerto Rico
-
Novartis VaccinesCompletedNovel Influenza A (H1N1) | A New Flu Virus of Swine OriginChile, Colombia, Germany, Switzerland
-
Novartis VaccinesCompletedA New Flu Virus of Swine Origin | Pandemic Influenza A (H1N1)Argentina, Netherlands
-
Mahidol UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Southeast Asia...Completed
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Pandemic Influenza | Influenza A Virus, H1N1 SubtypeIndia
-
The University of Hong KongWithdrawn
Clinical Trials on JNJ-63623872
-
Janssen Cilag N.V./S.A.Completed
-
Janssen Infectious Diseases BVBACompleted
-
Janssen-Cilag International NVTerminatedKidney Failure, ChronicGermany
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCNo longer availableH7N9 Subtype of Influenza A Virus
-
Janssen-Cilag International NVCompletedHepatic ImpairmentGermany
-
Janssen Research & Development, LLCCompleted
-
Janssen-Cilag International NVCompleted
-
Janssen Research & Development, LLCTerminatedInfluenza AUnited States, France, Korea, Republic of, Taiwan, China, India, Argentina, Israel, Thailand, Vietnam, Hungary, Germany, South Africa, Spain, Turkey, Belgium, Brazil, Canada, Mexico, New Zealand, Bulgaria, Peru, Malaysia, Italy, Estonia, ... and more